223 related articles for article (PubMed ID: 26628840)
1. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.
Puri P; Anand AC; Saraswat VA; Acharya SK; Dhiman RK; Sarin SK; Singh SP; Chawla YK; Aggarwal R; Amarapurkar D; Arora A; Dixit VK; Sood A; Shah S; Duseja A; Kapoor D; Shalimar ; Madan K; Pande G; Nagral A; Kar P; Koshy A; Puri AS; Eapen CE; Thareja S
J Clin Exp Hepatol; 2015 Sep; 5(3):221-38. PubMed ID: 26628840
[TBL] [Abstract][Full Text] [Related]
2. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.
Puri P; Saraswat VA; Dhiman RK; Anand AC; Acharya SK; Singh SP; Chawla YK; Amarapurkar DN; Kumar A; Arora A; Dixit VK; Koshy A; Sood A; Duseja A; Kapoor D; Madan K; Srivastava A; Kumar A; Wadhawan M; Goel A; Verma A; Shalimar ; Pandey G; Malik R; Agrawal S
J Clin Exp Hepatol; 2016 Jun; 6(2):119-45. PubMed ID: 27493460
[TBL] [Abstract][Full Text] [Related]
3. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.
Puri P; Anand AC; Saraswat VA; Acharya SK; Sarin SK; Dhiman RK; Aggarwal R; Singh SP; Amarapurkar D; Arora A; Chhabra M; Chetri K; Choudhuri G; Dixit VK; Duseja A; Jain AK; Kapoor D; Kar P; Koshy A; Kumar A; Madan K; Misra SP; Prasad MV; Nagral A; Puri AS; Jeyamani R; Saigal S; Shah S; Sharma PK; Sood A; Thareja S; Wadhawan M
J Clin Exp Hepatol; 2014 Jun; 4(2):117-40. PubMed ID: 25755549
[TBL] [Abstract][Full Text] [Related]
4. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
5. Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?
Premkumar M; Grover GS; Dhiman RK
J Clin Exp Hepatol; 2017 Sep; 7(3):253-261. PubMed ID: 28970713
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
Gupta V; Kumar A; Sharma P; Tyagi P; Bansal N; Singla V; Arora A
J Clin Exp Hepatol; 2014 Dec; 4(4):287-92. PubMed ID: 25755575
[TBL] [Abstract][Full Text] [Related]
9. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
10. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
Naik GS; Tyagi MG
J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
12. Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.
Gupta V; Kumar A; Sharma P; Bansal N; Singla V; Arora A
J Clin Exp Hepatol; 2015 Jun; 5(2):134-41. PubMed ID: 26155041
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model.
Dhiman RK; Grover GS; Premkumar M; Roy A; Taneja S; Duseja A; Arora S;
EClinicalMedicine; 2021 Nov; 41():101148. PubMed ID: 34712928
[TBL] [Abstract][Full Text] [Related]
16. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?
Anand AC
J Clin Exp Hepatol; 2017 Mar; 7(1):42-54. PubMed ID: 28348470
[TBL] [Abstract][Full Text] [Related]
17. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
[TBL] [Abstract][Full Text] [Related]
20. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
